John Theurer Cancer Center Presents Groundbreaking Studies in Blood Cancer at American Society of Hematology Meeting

John Theurer Cancer Center Presents Groundbreaking Studies in Blood Cancer at American Society of Hematology Meeting

The John Theurer Cancer Center at Hackensack University Medical Center, a member of Hackensack Meridian Health, today announced highlights of their data presentations that include 2 late-breaking abstracts, 19 oral sessions and 27 poster discussions at the 2016 American Society of Hematology (ASH) Annual Meeting, being held December 3-6, 2016 in San Diego. Seventeen physicians from the John Theurer Cancer Center will be presenting data at ASH.

“At ASH this year, John Theurer Cancer Center is proud to be part of 46 presentations of cutting-edge research in blood cancers that demonstrate the breadth and commitment to blood cancer research in our Institution,” said Andre Goy, M.D., chairman and director of John Theurer Cancer Center. “These high-impact data and advancements for the treatments of blood cancers will be especially meaningful and significant for cancer patients and their treating physicians.”

The data presentations at ASH bring forward advancements in three critical areas of research at JTCC:

  1. 1. Acute Myeloid Leukemia Novel Therapies
  2. 2. Multiple Myeloma Novel Options
  3. 3. Lymphoma Immunotherapy

Acute Myeloid Leukemia Novel Therapies

  • 591: Vadastuximab Talirine Plus Hypomethylating Agents: A Well-Tolerated Regimen with High Remission Rate in Frontline Older Patients with Acute Myeloid Leukemia (AML)
  • Oral presentation. Acute Myeloid Leukemia: Clinical Studies: New Drugs for Older AML
  • Monday, December 5, 2016: 7:30 AM; San Diego Ballroom AB, Marriott Marquis San Diego Marina
  • 590: Vadastuximab Talirine Monotherapy in Older Patients with Treatment Naive CD33-Positive Acute Myeloid Leukemia (AML)
  • Oral presentation. Acute Myeloid Leukemia: Clinical Studies: New Drugs for Older AML
  • Monday, December 5, 2016: 7:15 AM; San Diego Ballroom AB, Marriott Marquis San Diego Marina
  • 340: A Phase 1b Study of Vadastuximab Talirine As Maintenance and in Combination with Standard Consolidation for Patients with Acute Myeloid Leukemia (AML) Real-World Safety Experience for Short-Acting Recombinant Human Granulocyte Colony-Stimulating Factor.
  • Oral presentation. Acute Myeloid Leukemia: Clinical Studies: Optimizing Current AML Therapy
  • Sunday, December 4, 2016: 10:15 AM; Pacific Ballroom, Marriott Marquis San Diego Marina

Multiple Myeloma Novel Options

  • LBA-1: Comparison of Autologous Hematopoietic Cell Transplant (autoHCT), Bortezomib, Lenalidomide (Len) and Dexamethasone (RVD) Consolidation with Len Maintenance (ACM), Tandem Autohct with Len Maintenance (TAM) and Autohct with Len Maintenance (AM) for up-Front Treatment of Patients with Multiple Myeloma (MM): Primary Results from the Randomized Phase III Trial of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0702 – StaMINA Trial)
  • Late-Breaking Abstracts Session
  • Tuesday, December 6, 2016, 7:30 AM-9:00 AM; Hall AB, San Diego Convention Center
  • 2302: Long-Term Survival Is Demonstrated in Patients with Multiple Myeloma Treated with Allogeneic Hematopoietic Stem Cell Transplantation in Both the Consolidation and Salvage Settings.
  • Oral and poster presentation. Clinical Allogeneic Transplantation: Results: Poster I
  • Saturday, December 3, 2016, 5:30 PM-7:30 PM; Hall GH, San Diego Convention Center
  • 2110: Final Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study of Single-Agent Oprozomib in Patients with Hematologic Malignancies.
  • Oral and poster presentation. Myeloma: Therapy, excluding Transplantation: Poster I
  • Saturday, December 3, 2016, 5:30 PM-7:30 PM; Hall GH, San Diego Convention Center
  • 491: Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma (MM): STORM Study.
  • Oral and poster presentation. Myeloma: Therapy, excluding Transplantation: New Agents for Multiple Myeloma
  • Sunday, December 4, 2016: 5:30 PM; Hall AB, San Diego Convention Center

Lymphoma Immunotherapy

  • LBA-6: Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 ZUMA-1.
  • Late-Breaking Abstracts Session
  • Tuesday, December 6, 2016, 7:30 AM-9:00 AM; Hall AB, San Diego Convention Center
  • 1105: Preliminary Results from a Phase 1/2 Study of Brentuximab Vedotin in Combination with Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma
  • Oral and poster presentation. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Emerging Immunotherapy Approaches in Hodgkin Lymphoma
  • Monday, December 5, 2016: 4:30 PM; Room 6B, San Diego Convention Center
  • 183: A Phase 1 Study of Nivolumab in Combination with Ipilimumab for Relapsed or Refractory Hematologic Malignancies (CheckMate 039).
  • Oral presentation. Hodgkin Lymphoma and T/NK Cell Lymphoma—Clinical Studies: Novel Therapeutics and the Integration of PET Scans in Hodgkin Lymphoma and Peripheral T-Cell Lymphomas
  • Saturday, December 3, 2016: 2:30 PM; Room 6AB, San Diego Convention Center
  • 473: A Multicenter Open-Label, Phase 1b/2 Study of Ibrutinib in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
  • Oral presentation. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical Trials: Novel Approaches in Aggressive Lymphoma
  • Sunday, December 4, 2016: 5:30 PM; Room 6B, San Diego Convention Center

“JTCC is deeply committed to accelerating the development of breakthrough therapies to combat blood cancer and help patients and their families manage diseases like multiple myeloma and leukemia,” said Andrew L. Pecora, MD, FACP, CPE, chief innovation officer and president of Physician Services at Hackensack Meridian Health, who is recognized as an international expert in blood and marrow stem cell transplantation. “The groundbreaking work that our team is presenting this year further demonstrates the significant impact that our cancer program is having in the field of hematology.”

To view the abstracts from the ASH annual meeting with involvement from physicians at John Theurer Cancer Center please click here.

ABOUT THE JOHN THEURER CANCER CENTER AT HACKENSACK UNIVERSITY MEDICAL CENTER
The John Theurer Cancer Center at Hackensack University Medical Center is New Jersey’s largest and most comprehensive center dedicated to the diagnosis, treatment, management, research, screenings, and preventive care as well as survivorship of patients with all types of cancers. The 14 specialized divisions covering the complete spectrum of cancer care have developed a close-knit team of medical, research, nursing, and support staff with specialized expertise that translates into more advanced, focused care for all patients. Each year, more people in the New Jersey/New York metropolitan area turn to the John Theurer Cancer Center for cancer care than to any other facility in New Jersey. Housed within a 775-bed not-for-profit teaching, tertiary care, and research hospital, the John Theurer Cancer Center provides state-of-the-art technological advances, compassionate care, research innovations, medical expertise, and a full range of aftercare services that distinguish the John Theurer Cancer Center from other facilities.
www.jtcancercenter.org.

ABOUT HACKENSACK MERIDIAN HEALTH
Hackensack Meridian Health is a leading not-for-profit health care organization that is the most comprehensive and truly integrated health care network in New Jersey, offering a complete range of medical services, innovative research and life-enhancing care. Hackensack Meridian Health comprises 13 hospitals, including two academic medical centers, two children’s hospitals and nine community hospitals, physician practices, more than 120 ambulatory care centers, surgery centers, home health services, long-term care and assisted living communities, ambulance services, lifesaving air medical transportation, fitness and wellness centers, rehabilitation centers, and urgent care and after-hours centers. Hackensack Meridian Health has 28,000 team members, more than 6,000 physicians and is a distinguished leader in health care philanthropy, committed to the health and well-being of the communities it serves.

The Network’s notable distinctions include having one of only five major academic medical centers in the nation to receive Healthgrades America’s 50 Best Hospitals Award for five or more consecutive years, the number one hospital in New Jersey as ranked by U.S. News and World Report, consistently achieving Magnet® recognition for nursing excellence from the American Nurses Credentialing Center, recipient of the John M. Eisenberg Award for Patient Safety and Quality from The Joint Commission and the National Quality Forum, a six-time recipient of Fortune’s “100 Best Companies to Work For,” one of the “20 Best Workplaces in Health Care” in the nation, and the number one “Best Place to Work for Women.” Hackensack Meridian Health is a member of AllSpire Health Partners, an interstate consortium of leading health systems, to focus on the sharing of best practices in clinical care and achieving efficiencies.

The hospitals of Hackensack Meridian Health include: academic medical centers – HackensackUMC in Hackensack, Jersey Shore University Medical Center in Neptune; children’s hospitals – Joseph M. Sanzari Children’s Hospital in Hackensack, K. Hovnanian Children’s Hospital in Neptune; community hospitals – Ocean Medical Center in Brick, Riverview Medical Center in Red Bank, HackensackUMC Mountainside in Montclair, HackensackUMC Palisades in North Bergen, Raritan Bay Medical Center in Perth Amboy, Southern Ocean Medical Center in Manahawkin, Bayshore Community Hospital in Holmdel, Raritan Bay Medical Center in Old Bridge, and HackensackUMC at Pascack Valley in Westwood.